Tethys AS® Aspiration Catheter, which is an acute ischemic stroke（AIS）revascularization product developed by Achieva Medical (“Achieva”), a wholly-owned subsidiary of the Company, is approved by the National Medical Products Administration (the “NMPA”) on May 18, 2022. The registration approval marks the further expansion of Achieva’s product portfolio for acute ischemic stroke treatment.

 

Tethys AS® Aspiration Catheter provides an effective solution for thrombus removal, featuring a wide lumen and easy positioning. The 0.071-inch wide lumen of Tethys AS® Aspiration Catheter largely increases the aspiration force, which can significantly shorten the procedure time. It features a longer soft segment at the distal end, which conforms to the tortuous vessels and largely enhances its deliverability to the distal vessels. The optimized design of the transitional structure improves the trackability of the catheter, allowing the device to be delivered to the target vessel more easily. The entire device adopts a double-layer design with outer braids and inner coils, which allows high compressive strength and helps maintain lumen integrity. Tethys AS® aspiration catheter is available in 2 inner diameters and 4 effective lengths, with 14 different models in total. Physicians can select a proper model based on their preferences and the clinical manifestations of patients.

 

According to a number of high-quality clinical studies, direct aspiration has become as a first line treatment technique for patients with AIS. Achieva offers total treatment solutions for AIS patients, including Tethys AS® Aspiration Catheter, Syphonet® Stent Retriever, Tethys® Intermediate Catheter, Presgo® Micro Guidewire, Presgo® Microcatheter, and Fluxcap® Balloon Guiding Catheter (to be approved), to address the clinical needs in mechanical thrombectomy. Physicians can choose different Achieva’s product combinations based on the demands of patients and physicians. Achieva will continue to enrich the product deployment in the aspect of ischemic stroke, facilitate the construction of domestic stroke centers and popularize the interventional treatment of ischemic stroke patients.